Abstract
Chronic inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and asthma, are characterized by long-term inflammation that significantly impacts patients' quality of life. Conventional drug therapies often face challenges related to efficacy, side effects, and patient compliance. In response, recent advancements in biopharmaceutical drug delivery systems have aimed at improving the targeted delivery, bioavailability, and therapeutic efficacy of drugs. This article reviews the latest developments in drug delivery technologies for chronic inflammatory diseases, including nanoparticles, liposomes, biologics, and gene therapy. Additionally, it discusses the future potential of these systems in transforming the treatment landscape for chronic inflammation.
All articles published in the American Journal of Pharmaceutics are open access and licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows users to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given, a link to the license must be provided, and any changes must be indicated.
-
Authors retain full copyright of their work.
-
The journal does not restrict reuse of content, provided proper citation of the original publication is made.